Portal de Periódicos da CAPES

Whole body PD-1 and PD-L1 positron emission tomography in patients with non-small-cell lung cancer

2018; Nature Portfolio; Volume: 9; Issue: 1 Linguagem: Inglês

10.1038/s41467-018-07131-y

2041-1723

Anna-Larissa N. Niemeijer, David Leung, Marc C. Huisman, Idris Bahce, Otto S. Hoekstra, Guus A.M.S. van Dongen, Ronald Boellaard, Shuyan Du, Wendy Hayes, Ralph C. Smith, Albert D. Windhorst, N. Harry Hendrikse, Alex J. Poot, Daniëlle J. Vugts, Erik Thunnissen, Paul E. Morin, Daša Lipovšek, David J. Donnelly, Samuel J. Bonacorsi, Lauren Velasquez, Tanja D. de Gruijl, Egbert F. Smit, Adrianus J. de Langen,

Lung Cancer Diagnosis and Treatment

Abstract PD-L1 immunohistochemistry correlates only moderately with patient survival and response to PD-(L)1 treatment. Heterogeneity of tumor PD-L1 expression might limit the predictive value of small biopsies. Here we show that tumor PD-L1 and PD-1 expression can be quantified non-invasively using PET-CT in patients with non-small-cell lung cancer. Whole body PD-(L)1 PET-CT reveals significant tumor tracer uptake heterogeneity both between patients, as well as within patients between different tumor lesions.